Mobocertinib is a tolerable and possible treatment option for patients with EGFR exon 20 insertion mutated advanced non-small-cell lung cancer | 2 Minute Medicine
2 Minute Medicine ,
1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the EXCLAIM cohort (independe…